Douglas Fiedler, MD
Pulmonary Disease · Lincoln, NENPI 1215976147
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (28.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Inspire Medical Systems, Inc. accounts for 85.5% of it on its own, with 34 other manufacturers making up the rest. 2025 is the largest year on record at $17,564, more than ten times the $731 reported in 2019. Among pulmonary disease clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 254 payments — averaging $91.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$20K
- Grifols USA, LLC$449
- AstraZeneca$367
- Harmony Biosciences LLC$275
- Amgen$254
- Sunovion Pharmaceuticals Inc.$236
- plus $2K from 29 others
What the payments were for
- Consulting fees$6,65029%
- Speaking & faculty fees$4,00017%
- Travel & lodging$6,23927%
- Food & beverage$6,27527%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 66 | $19,893 |
| Grifols USA, LLC | 25 | $449 |
| AstraZeneca | 4 | $367 |
| Harmony Biosciences LLC | 13 | $275 |
| Amgen | 18 | $254 |
| Sunovion Pharmaceuticals Inc. | 14 | $236 |
| Sanofi | 14 | $214 |
| Boehringer Ingelheim | 13 | $201 |
| GSK | 22 | $171 |
| Philips North America LLC | 4 | $154 |
| Jazz Pharmaceuticals Inc. | 8 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $105 |
| Regeneron Healthcare Solutions, Inc. | 6 | $97 |
| Johnson & Johnson | 5 | $75 |
| Verona Pharma, Inc. | 3 | $56 |
| Axsome Therapeutics, Inc. | 2 | $56 |
| United Therapeutics Corporation | 3 | $54 |
| Genentech USA, Inc. | 4 | $53 |
| Resmed Corp | 1 | $48 |
| Mylan Specialty L.p. | 3 | $44 |
| Insmed, Inc. | 3 | $43 |
| Baxter Healthcare | 2 | $33 |
| Pfizer | 2 | $29 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $28 |
| Bayer | 2 | $27 |
| Shire North American Group Inc | 2 | $24 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| AbbVie | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Novartis | 1 | $14 |
| Merck | 1 | $14 |
| Viatris Specialty LLC | 1 | $14 |
| Circassia Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,264 in reported general payments places this provider in the 90th percentile of 81 pulmonary disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 11 | $144,009 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 146 | $116,249 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 87 | $52,699 |
| Breo ElliptaFluticasone/Vilanterol | 56 | $24,448 |
| Spiriva RespimatTiotropium Bromide | 13 | $14,954 |
| XareltoRivaroxaban | 21 | $14,311 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $12,784 |
| Spiriva HandihalerTiotropium Bromide | 17 | $11,725 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $9,810 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $8,331 |
| Wixela InhubFluticasone Propion/Salmeterol | 32 | $6,321 |
| DuleraMometasone/Formoterol | 12 | $5,790 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 144 | $3,040 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 26 | $2,624 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $2,044 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $171 | $203,206304 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $201 | $167,29336 claims |
| Johnson & JohnsonXarelto | $75 | $14,31121 claims |
| AstraZenecaBreztri Aerosphere | $367 | $12,78421 claims |
| MerckDulera | $14 | $5,79012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 81 pulmonary disease providers in Nebraska.
Other pulmonary disease in Lincoln
- Ryan MartinLincoln$600K
- Kevin ReichmuthLincoln$22K
- Harvey HopkinsLincoln$18K
- William JohnsonLincoln$18K
- Matthew MaslonkaLincoln$14K
- Jakeb RiggleLincoln$13K
- Jonathan SpencerLincoln$9K
- Louis VioliLincoln$6K
- Jeffrey JarrettLincoln$5K
- Sean BarryLincoln$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.